Cargando…
686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
BACKGROUND: Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-positive (GP) and anaerobic isolates from Phase 3 ABSSSI clini...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811122/ http://dx.doi.org/10.1093/ofid/ofz360.754 |
_version_ | 1783462404154195968 |
---|---|
author | Yang, Yang Zhu, Demei |
author_facet | Yang, Yang Zhu, Demei |
author_sort | Yang, Yang |
collection | PubMed |
description | BACKGROUND: Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-positive (GP) and anaerobic isolates from Phase 3 ABSSSI clinical trials were determined. METHODS: 313 isolates were collected from 65 participated sites and sent to a central laboratory for MIC testing. Clinical isolates included 34 anaerobes (15 Finegoldia magna, 8 Actinomyces spp., 4 Prevotella spp., 3 Propionibacterium avidum, 2 Peptostreptococcus spp., 1 Veillonella spp. and 1 Bacteroides fragilis), 187 S. aureus (59.7%). 12 S. pyogenes, 5 Enterococcus, and 75 other Gram-positive organisms. Broth micro-dilution method was used to determine the MIC of contezolid, linezolid, and other comparators to facultative isolates. Agar dilution was carried out for the anaerobes. RESULTS: For both 33 MRSA and 154 MSSA MIC(50/90) values of contezolid and linezolid were 2 mg/L. One E. faecalis showed decreased susceptibility to oxazolidinones (both MIC = 4). 1 mg/L contezolid and linezolid could inhibit 12 S. pyogenes. 2 mg/L contezolid and linezolid could inhibit 15 Finegoldia magna. 0.5 mg/L contezolid and linezolid could inhibit 8 Actinomyces spp. To one Bacteroides fragili, two Prevotella bivia and one Leuconostoc lactis (Intrinsic resistant to vancomycin) the MIC of contezolid were 4 or 8 mg/L. In general, Contezolid had lower or equal MIC(50/90) values against both GP and ANA species compared with linezolid for all organisms. CONCLUSION: Contezolid demonstrated potent in vitro antibacterial activity against Gram-positive and anaerobic isolates tested. These data suggest that contezolid might be a beneficial supplement to the arena against MDR Gram-positive infection. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6811122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68111222019-10-28 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) Yang, Yang Zhu, Demei Open Forum Infect Dis Abstracts BACKGROUND: Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-positive (GP) and anaerobic isolates from Phase 3 ABSSSI clinical trials were determined. METHODS: 313 isolates were collected from 65 participated sites and sent to a central laboratory for MIC testing. Clinical isolates included 34 anaerobes (15 Finegoldia magna, 8 Actinomyces spp., 4 Prevotella spp., 3 Propionibacterium avidum, 2 Peptostreptococcus spp., 1 Veillonella spp. and 1 Bacteroides fragilis), 187 S. aureus (59.7%). 12 S. pyogenes, 5 Enterococcus, and 75 other Gram-positive organisms. Broth micro-dilution method was used to determine the MIC of contezolid, linezolid, and other comparators to facultative isolates. Agar dilution was carried out for the anaerobes. RESULTS: For both 33 MRSA and 154 MSSA MIC(50/90) values of contezolid and linezolid were 2 mg/L. One E. faecalis showed decreased susceptibility to oxazolidinones (both MIC = 4). 1 mg/L contezolid and linezolid could inhibit 12 S. pyogenes. 2 mg/L contezolid and linezolid could inhibit 15 Finegoldia magna. 0.5 mg/L contezolid and linezolid could inhibit 8 Actinomyces spp. To one Bacteroides fragili, two Prevotella bivia and one Leuconostoc lactis (Intrinsic resistant to vancomycin) the MIC of contezolid were 4 or 8 mg/L. In general, Contezolid had lower or equal MIC(50/90) values against both GP and ANA species compared with linezolid for all organisms. CONCLUSION: Contezolid demonstrated potent in vitro antibacterial activity against Gram-positive and anaerobic isolates tested. These data suggest that contezolid might be a beneficial supplement to the arena against MDR Gram-positive infection. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811122/ http://dx.doi.org/10.1093/ofid/ofz360.754 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Yang, Yang Zhu, Demei 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title | 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title_full | 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title_fullStr | 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title_full_unstemmed | 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title_short | 686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) |
title_sort | 686. evaluation of contezolid activity to anaerobic and gram-positive-cocci isolates from a phase 3 acute bacterial skin and skin structure infection clinical trial (mrx-i-06) |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811122/ http://dx.doi.org/10.1093/ofid/ofz360.754 |
work_keys_str_mv | AT yangyang 686evaluationofcontezolidactivitytoanaerobicandgrampositivecocciisolatesfromaphase3acutebacterialskinandskinstructureinfectionclinicaltrialmrxi06 AT zhudemei 686evaluationofcontezolidactivitytoanaerobicandgrampositivecocciisolatesfromaphase3acutebacterialskinandskinstructureinfectionclinicaltrialmrxi06 |